Clinical Trial Results:
Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
Summary
|
|
EudraCT number |
2015-005404-29 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
14 Sep 2012
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
09 Jun 2016
|
First version publication date |
09 Jun 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
E2I60
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01491087 | ||
WHO universal trial number (UTN) |
U1111-1117-7233 | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur, SA
|
||
Sponsor organisation address |
2, avenue Pont Pasteur, Lyon cedex 07, France, F-69367
|
||
Public contact |
Medical Product Leader, Sanofi Pasteur, SA, 33 4 37 65 67 99, Emmanuel.vidor@sanofipasteur.com
|
||
Scientific contact |
Medical Product Leader, Sanofi Pasteur, SA, 33 4 37 65 67 99, Emmanuel.vidor@sanofipasteur.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Dec 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Sep 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To describe the safety after administration of PENTAXIM® at 2, 3, and 4 months of age in the study population.
|
||
Protection of trial subjects |
Only subjects that met all the study inclusion and none of the exclusion criteria were randomized and vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment were available on site in case of any immediate allergic reactions.
|
||
Background therapy |
Not applicable | ||
Evidence for comparator |
Not applicable | ||
Actual start date of recruitment |
02 Dec 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
China: 900
|
||
Worldwide total number of subjects |
900
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
900
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||
Recruitment
|
|||||||||||||||||
Recruitment details |
Study subjects were enrolled from 02 December 2011 to 14 May 2012 in 3 Chinese provinces/cities. | ||||||||||||||||
Pre-assignment
|
|||||||||||||||||
Screening details |
A total of 900 subjects who met the inclusion, but none of the exclusion criteria were enrolled and vaccinated. | ||||||||||||||||
Period 1
|
|||||||||||||||||
Period 1 title |
Overall (overall period)
|
||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||
Blinding implementation details |
Not applicable
|
||||||||||||||||
Arms
|
|||||||||||||||||
Arm title
|
Study Group | ||||||||||||||||
Arm description |
Subjects received DTacP-IPV//PRP~T Combined Vaccine (Pentaxim®) as a three-dose primary vaccination at 2, 3, and 4 Months of Age. | ||||||||||||||||
Arm type |
Experimental | ||||||||||||||||
Investigational medicinal product name |
DTacP-IPV//PRP-T combined vaccine
|
||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||
Other name |
PENTAXIM™
|
||||||||||||||||
Pharmaceutical forms |
Powder and suspension for suspension for injection
|
||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||
Dosage and administration details |
0.5 mL, Intramuscular into the anterolateral external aspect of the upper thigh (right or left)
|
||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Study Group
|
||
Reporting group description |
Subjects received DTacP-IPV//PRP~T Combined Vaccine (Pentaxim®) as a three-dose primary vaccination at 2, 3, and 4 Months of Age. |
|
|||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Infant Subjects with Solicited Injection-site and Systemic Reactions After Any Injection with DTacP-IPV//PRP~T Combined Vaccine (Pentaxim®) Given as a Three-Dose Primary Vaccination. [1] | ||||||||||||||||||||||||||||||||||||||||||||
End point description |
Solicited injection-site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever (temperature), Vomiting, Crying abnormal, Drowsiness, Appetite Lost, and Irritability.
Grade 3 injection-site: Tenderness, Cries when injected limb is moved, or the movement of the injected limb is reduced; Erythema and Swelling > 30 mm. Grade 3: Fever, > 39°C; Vomiting, ≥ 6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, > 3 hours; Drowsiness, Sleeping most of the time or difficult to wake up; Appetite Lost, Refuses ≥ 3 feeds/meals or refuses most feeds/meals; and Irritability, Inconsolable.
|
||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up to Day 7 post-any vaccination
|
||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses was performed based on the study vaccine administered for this outcome. |
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Infant Subjects with Solicited Injection-site and Systemic Reactions After Each Injection with DTacP-IPV//PRP~T Combined Vaccine (Pentaxim®) Given as a Three-Dose Primary Vaccination. [2] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Solicited injection-site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever (temperature), Vomiting, Crying abnormal, Drowsiness, Appetite Lost, and Irritability.
Grade 3 injection-site: Tenderness, Cries when injected limb is moved, or the movement of the injected limb is reduced; Erythema and Swelling > 30 mm. Grade 3: Fever, > 39°C; Vomiting, ≥ 6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, > 3 hours; Drowsiness, Sleeping most of the time or difficult to wake up; Appetite Lost, Refuses ≥ 3 feeds/meals or refuses most feeds/meals; and Irritability, Inconsolable.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 up Day 7 post-each vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive analyses was performed based on the study vaccine administered for this outcome. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were reported from Day 0 (post-vaccination) up to Day 42 post-third vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Study Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received DTacP-IPV//PRP~T Combined Vaccine (Pentaxim®) as a three-dose primary vaccination at 2, 3, and 4 Months of Age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None. |